LDLR and atherosclerosis: Administration of KRP-203, a S1PR1 agonist, reduced the development of atherosclerosis in LDL receptor-deficient mice on a cholesterol-rich diet by modulating the lymphocyte and macrophage function and improving the endothelial barrier (84).